CCNU, vinblastine, and delalutin therapy in renal cell carcinoma.
Advanced renal cell carcinoma is relatively resistant to most adequately evaluated chemotherapeutic agents. The combination of CCNU and vinblastine, which has antitumor activity in a frog renal carcinoma model system, has demonstrated activity in initial studies in man. The current study investigated this combination of drugs together with a progestational agent, Delalutin. Seventeen patients with metastatic renal cell carcinoma were treated with CCNU, vinblastine and Delalutin. There were no objective responses. Four patients with stable disease had a mean survival of 18 months compared to 13 patients with progressive disease who had a mean survival of 5 months. The survival of the four patients with stable disease was in large part due to the slowly progressive natural history of their disease.
D000230:Adenocarcinoma / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D006908:Hydroxyprogesterones / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008130:Lomustine / Q000008:administration & dosage*; D009362:Neoplasm Metastasis; D009607:Nitrosourea Compounds / Q000008:administration & dosage*; D014747:Vinblastine / Q000008:administration & dosage*
D006908:Hydroxyprogesterones; D009607:Nitrosourea Compounds; D014747:Vinblastine; D008130:Lomustine